Call Options

13 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$13.15 - $20.45 $26,300 - $40,900
-2,000 Reduced 14.39%
11,900 $4,000
Q1 2022

May 12, 2022

SELL
$14.54 - $21.5 $4.92 Million - $7.27 Million
-338,100 Reduced 96.05%
13,900 $21,000
Q4 2020

Feb 16, 2021

BUY
$35.35 - $50.67 $791,840 - $1.14 Million
22,400 Added 6.8%
352,000 $9,000
Q3 2020

Nov 13, 2020

SELL
$35.98 - $47.66 $7.73 Million - $10.2 Million
-214,900 Reduced 39.47%
329,600 $34,000
Q2 2020

Aug 10, 2020

SELL
$45.06 - $67.74 $5.07 Million - $7.62 Million
-112,500 Reduced 17.12%
544,500 $102,000
Q1 2020

May 08, 2020

BUY
$40.01 - $73.97 $19.8 Million - $36.5 Million
494,100 Added 303.31%
657,000 $1.16 Million
Q4 2019

Feb 11, 2020

SELL
$37.13 - $74.62 $3.3 Million - $6.64 Million
-89,000 Reduced 35.33%
162,900 $886,000
Q3 2019

Nov 12, 2019

BUY
$39.36 - $76.8 $527,424 - $1.03 Million
13,400 Added 5.62%
251,900 $507,000
Q2 2019

Aug 14, 2019

BUY
$52.76 - $82.19 $7.22 Million - $11.3 Million
136,900 Added 134.74%
238,500 $4.91 Million
Q1 2019

May 10, 2019

SELL
$27.39 - $68.41 $15.9 Million - $39.7 Million
-580,200 Reduced 85.1%
101,600 $2.46 Million
Q4 2018

Feb 12, 2019

BUY
$22.8 - $33.93 $20,520 - $30,537
900 Added 0.13%
681,800 $5,000
Q3 2018

Nov 09, 2018

BUY
$29.75 - $43.08 $17.3 Million - $25 Million
580,700 Added 579.54%
680,900 $5.1 Million
Q2 2018

Aug 13, 2018

BUY
$21.96 - $39.94 $2.2 Million - $4 Million
100,200 New
100,200 $1.8 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.